Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation? Authors' reply

Affiliations

¹ Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA.
² Division of Health Care Delivery Research, Mayo Clinic, Jacksonville, Florida, USA.
³ School of Pharmacy, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA.
⁴ Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.

Editorial

Freddy Caldera et al. Aliment Pharmacol Ther. 2023 Jun.

. 2023 Jun;57(11):1345-1346.

doi: 10.1111/apt.17519.

¹ Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA.
² Division of Health Care Delivery Research, Mayo Clinic, Jacksonville, Florida, USA.
³ School of Pharmacy, University of Wisconsin-Madison, School of Medicine & Public Health, Madison, Wisconsin, USA.
⁴ Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.

No abstract available

Comment on

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease.
Caldera F, Spaulding AC, Borah B, Moriarty J, Zhu Y, Hayney MS, Farraye FA. Caldera F, et al. Aliment Pharmacol Ther. 2023 Jun;57(11):1326-1334. doi: 10.1111/apt.17454. Epub 2023 Mar 10. Aliment Pharmacol Ther. 2023. PMID: 36896952
Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation?
Macaluso FS, Orlando A. Macaluso FS, et al. Aliment Pharmacol Ther. 2023 Jun;57(11):1343-1344. doi: 10.1111/apt.17490. Aliment Pharmacol Ther. 2023. PMID: 37161634 No abstract available.

1. Macaluso FSO. Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for univeral recommendation? Aliment Pharmacol Ther. 2023;57:1343-4.
1. Caldera F, Spaulding AC, Borah B, Moriarty J, Zhu Y, Hayney MS, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57:1326-34. https://doi.org/10.1111/apt.17454
1. Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: Recommendations of the Advisory Committee on Immunization Practices-United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(3):80-4.
1. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(4):420-9.
1. Khan N, Patel D, Trivedi C, Shah Y, Lichtenstein G, Lewis J, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a Nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16(12):1919-1927.e1913.